Berkeley settlement
This article was originally published in The Tan Sheet
Executive Summary
A court case filed in the district court of Dallas County, Texas precludes the five companies owned by Steven Warshak - including Berkeley Premium Nutraceuticals - from fraudulently marketing 15 dietary supplements in the state. The banned supplements include male enhancement supplement Enzyte, noted for its "Smiling Bob" commercials. The case also stops deceptive "free trial" offers for the dietary supplements. Under the Feb. 1 settlement, Warshak will pay the state of Texas $350,000 in civil penalties and attorneys' fees. In September 2006 a federal grand jury indicted Berkeley Premium Nutraceuticals, Warshak, his mother and five additional co-conspirators on a total of 112 criminal charges (1"The Tan Sheet," Sept. 25, 2006, In Brief)...
You may also be interested in...
“Crying” Bob
A federal grand jury indicted Berkeley Premium Nutraceuticals, the company's President Steve Warshak, his mother and five additional defendants and co-conspirators on a total of 112 criminal charges Sept. 20. Warshak engaged in conspiracy to commit mail, wire and bank fraud, money laundering, conspiracy to obstruct proceedings before FTC and other criminal acts, U.S. Attorney for the Southern District of Ohio Gregory Lockhart alleges. Warshak, et al., defrauded consumers of more than $100 mil., according to Lockhart. If convicted, the defendants are expected to forfeit assets including several parcels of land, vehicles, and the contents of numerous bank and investment accounts, according to the filing. Berkeley, marketer of male enhancement supplement Enzyte, settled with the Attorney Generals of six states in March for $2.5 mil. (1"The Tan Sheet" March 6, 2006, p. 8). Earlier this month, the Cincinnati, Ohio-based firm issued a press release asserting they had reduced consumer complaints by 90% (2"The Tan Sheet" Sept. 11, 2006, In Brief)....
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: